ISPOR STUDENT MEMBERS GAIN ACCESS TO FORMULARYDECISIONS.COM®

Published Dec 1, 2015
Princeton, NJ—December 1, 2015—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today a new Student Network benefit that now provides ISPOR student members with complimentary access to FormularyDecisions.com®.  FormularyDecisions.com® is a centralized, web-based payer ecosystem developed by Dymaxium Inc. that connects current and future health care decision makers with evidence from leading scientific sources, insights from health technology assessment (HTA) and other authoritative reviews, and tools to efficiently evaluate and compare life science products for evidence-based decisions. Current ISPOR student members can access this new benefit online at http://www.ispor.org/student/FormularyDecisions.asp by logging in with their ISPOR student member information. Future ISPOR student members can find out more and apply for membership at http://www.ispor.org/members/MembershipIndex.aspx. ISPOR student members must be full-time graduates or undergraduate students or academic fellows and must show proof of current enrollment.

###

Related Stories

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×